222854-50-4

Upstream product

• 1991-81-7 4-iodo-L-phenylalanine 
• 115-11-7 isobutene 

Downstream Products

• 225528-05-2 N-Fmoc-(L)-4-iodophenylalanine t-butyl ester 
• 958236-61-8 5-{4-[2-tert-butoxycarbonyl-2-(2,4,6-trimethyl-benzoylamino)-ethyl]-phenyl}-isoxazole-3-carboxylic acid ethyl ester 
• 958236-62-9 3-[4-(3-formyl-isoxazol-5-yl)-phenyl]-2-(2,4,6-trimethyl-benzoylamino)-propionic acid tert-butyl ester 
• 217326-47-1 4-iodo-(L)-phenylalanine, tert-butyl ester hydrochloride 

Relevant academic research and scientific papers

N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.

Given the proposed involvement of VLA-4 in inflammatory processes, a program to identify orally active VLA-4 antagonists was initiated. Herein, we report the discovery of a N-tetrahydrofuroyl-(L)-phenylalanine derivative (17) and related analogues as potent VLA-4 antagonists with good oral bioavailability.

NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF

The present invention is related to a compound of formula (I), wherein A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a radical individually and independently selected from the group comprising (CH2)n-E-(CH2)m-L-(CH2)k and (CH2)m-L-(CH2)k, wherein E is a radical which is either absent or present, whereby if E is present, E is selected from the group comprising O, S, NH, NRa, CO, SO, SO2, acetylene and substituted ethylene; L is a radical which is either absent or present, whereby if L is present, L is individually and independently selected from the group comprising O, S, NH, NRb, CO, SO, SO2, substituted ethylene and acetylene; and k, m and n are individually and independently O, 1, 2 or 3; ψ is a radical of formula (II), wherein Q is a radical selected from the group comprising a direct bond, Cl-C4alkyl, C=O, C=S, O, S, CRaRb, NRa-NRb, N=N, CRa=N, N=CRa, (C=O)-O, 0-(C=O), SO2, NRa, (C=O)-NR3, NRa-(C=0)-NRb, NRC-(C=O), 0-(C=0)-NRc, NRc-(C=0)-0, NRC-(C=S), (C=S)-NRc, NRc-(C=S)-NRd, NRC-SO2 and SO2-NRc. R1, Ra, Rb, Rc and Rd are radicals which are individually and independently selected from the group comprising H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloyl, substituted heterocycloyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy, alkyloxyalkyl, substituted alkyloxyalkyl, alkyloxycycloalkyl, substituted alkyloxycycloalkyl, alkyloxyheterocyclyl, substituted alkyloxyheterocyclyl, alkyloxyaryl, substituted alkyloxyaryl, alkyloxyheteroaryl, substituted alkyloxyheteroaryl, alkylthioalkyl, substituted alkylthioalkyl, alkylthiocycloalkyl and substituted alkylthiocycloalkyl, hydroxy, substituted hydroxy, oxo, thio, substituted thio, aminocarbonyl, substituted aminocarbonyl, formyl, substituted formyl, thioformyl, substituted thioformyl, amino, substituted amino, hydroxy 1, substituted hydroxy 1, mercapto, substituted mercapto, hydrazino, substituted hydrazino, diazene, substituted diazene, imine, substituted imine, amidino, substituted amidino, iminomethylamino, substituted iminomethylamino, ureido, substituted ureido, formylamino, substituted formylamino, aminocarbonyloxy, substituted aminocarbonyloxy, hydroxycarbonylamino, substituted hydroxycarbonylamino, hydroxycarbonyl, substituted hydroxycarbonyl, formyloxy, substituted formyloxy, thioformylamino, substituted thioformylamino, aminothiocarbonyl, substituted aminothiocarbonyl, thioureido, substituted thioureido, sufonyl, substituted sulfonyl, sulfonamino, substituted sulfonamino, aminosulfonyl, substituted aminosulfonyl, cyano and halogen; R2 is a hydrophobic moiety; R3 is a radical selected from the group comprising OH, C1C8alkyloxy and aryl C0-C6alkyloxy; R4 is a radical selected from the group comprising hydrogen, halogen and C1-C4alkyl; and G is a radical containing a basic moiety.

Substituted ureas as cell adhesion inhibitors

Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.